May, 2018

Global
News / Media
TOKYO – May 16, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that a wide selection of abstracts highlighting the Company’s diverse oncology portfolio across a broad range of cancers have been accepted for oral and poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5 in Chicago. Highlig...
Read More
Global
News / Media
VANCOUVER, British Columbia, May 9, 2018 and TOKYO, Japan, May 10, 2018 – Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP, “Aquinox”), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced an exclusive license agreement (“Agreement”) for Japan...
Read More
Global
News / Media
TOKYO, May 7, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urinary i...
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.